Company Overview

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of oral small-molecule medicines targeting rare diseases. The company operates primarily within the biopharmaceutical and rare disease therapeutics industries, with a strategic emphasis on diseases driven by dysregulated immune and inflammatory pathways. Its business model centers on advancing proprietary compounds from internal research through late-stage development and global commercialization.

The company’s primary revenue drivers are its approved products Orladeyo (berotralstat) for hereditary angioedema (HAE) and Joenja (leniolisib) for activated phosphoinositide 3-kinase delta syndrome (APDS), alongside government-related sales of Rapivab (peramivir) for influenza. BioCryst serves specialist physicians, hospitals, and rare disease patient populations, with a particular focus on immunology and complement-mediated disorders. Founded in 1986, BioCryst originally focused on structure-based drug design and antiviral research, later evolving into a commercial-stage rare disease company through internal R&D, licensing transactions, and targeted acquisitions.

Business Operations

BioCryst operates through a single integrated reporting structure, with revenue generated from product sales, government procurement contracts, and collaborative agreements. Commercial operations are driven primarily by Orladeyo and Joenja, which are marketed directly in the United States and through partners in certain international markets. Rapivab contributes episodic revenue, largely tied to U.S. government stockpiling and pandemic preparedness programs.

The company controls a portfolio of proprietary oral small-molecule technologies targeting enzymes and pathways involved in immune regulation, including the kallikrein and PI3Kδ pathways. BioCryst does not operate large-scale manufacturing facilities and relies on third-party manufacturers for drug substance and finished product. Its wholly owned subsidiary Palobiofarma S.L., based in Spain, supports early-stage research and discovery efforts, while commercial and regulatory activities are managed from the United States with support from international partners.

Strategic Position & Investments

BioCryst’s strategic direction is centered on becoming a leading rare disease company with sustainable profitability driven by high-value, chronic therapies. Growth initiatives focus on expanding Orladeyo penetration in global HAE markets, broadening Joenja access for APDS patients worldwide, and advancing earlier-stage pipeline programs targeting complement-mediated and genetic diseases.

Key investments include the acquisition of Palobiofarma S.L., which strengthened the company’s medicinal chemistry capabilities, and the in-licensing of Joenja from Novartis AG, providing BioCryst with a first-in-class therapy for APDS. The company continues to invest in next-generation oral inhibitors and lifecycle management programs designed to extend its presence in immunology and rare disease markets. Pipeline development remains focused, with capital allocation prioritized toward programs with clear regulatory and commercial pathways.

Geographic Footprint

BioCryst is headquartered in North Carolina, United States, and maintains its primary executive, commercial, and regulatory operations there. The company has a significant operational presence in Europe through Spain, where Palobiofarma S.L. supports discovery research, and through regulatory and commercial activities tied to European product approvals.

Commercial reach extends across North America, Europe, and parts of Asia-Pacific, with products approved and sold in multiple countries either directly or via regional partners. International operations are supported through distribution and commercialization agreements, giving BioCryst exposure to global rare disease markets without maintaining extensive physical infrastructure outside the United States.

Leadership & Governance

BioCryst is led by an experienced management team with backgrounds in biotechnology, rare diseases, and global pharmaceutical commercialization. Leadership emphasizes disciplined capital allocation, scientific rigor, and long-term value creation through focused execution in rare disease markets.

Key executives include:

• Jon P. Stonehouse – President and Chief Executive Officer
• Anthony Doyle – Chief Financial Officer
• Helen Thackray – Chief Operating Officer
• William P. Sheridan – Chief Medical Officer
• Alison Green – Chief Legal and Administrative Officer

The leadership team’s strategic vision centers on building a sustainable, profitable rare disease company by leveraging oral small-molecule innovation, targeted global expansion, and operational efficiency, while maintaining governance practices consistent with U.S. public company standards.